Advice
in the absence of a submission from the holder of the marketing authorisation:
decitabine/cedazuridine (Inaqovi)®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice234KB (PDF)
Medicine details
- Medicine name:
- decitabine cedazuridine (Inaqovi)
- SMC ID:
- SMC2681
- Indication:
As monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.
- Pharmaceutical company
- Otsuka Pharmaceutical Europe
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 June 2024